← Leaderboards
Zaijie Jim Wang
University Of Illinois At Chicago
$13,634,711
Attributed
$18,290,352
Total exposure
13
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,290,352 · 13
By mechanism
R01$9,788,183 · 4
R35$5,720,342 · 2
R21$1,754,289 · 4
K07$675,960 · 1
K01$344,078 · 1
R13$7,500 · 1
Top collaborators
- Robert E Molokie7 shared
- Frank Porreca6 shared
- Diana J Wilkie6 shared
- Christian Peters2 shared
- Andrew Riley2 shared
- Lisa Tussing-Humphreys1 shared
Most similar at University Of Illinois At Chicago
Same institution · by research overlap
- Guido F Pauli$8,225,012
- Judy L. Bolton$10,491,560
- Norman R Farnsworth$4,328,955
- Rachel L Ruhlen$139,200
- Kimberly Bean$169,124
Others in their field
Top investigators on “Pain”
- Emer Leahy · Psychogenics, Inc.$49,781,254
- Lynn Larson Debar · Kaiser Foundation Research Institute$37,527,482
- J Richard Landis · University Of Pennsylvania$34,799,488
- Clifford J Woolf · Boston Children'S Hospital$30,992,766
- Emeran A Mayer · University Of California Los Angeles$29,229,798
- Pamela Susan Douglas · Duke University$28,862,172
Research focus
PainChronic PainAmericanChronicReportingMolecularSymptomsInnovationSickle Cell AnemiaBasePharmacologyLiteratureAfricanTransgenic MiceNeurotransmittersSuccessAcute PainResponseFutureMouse ModelProgramsSicklingReceptorHyperalgesia
Grant awards (45)
Molecular Mechanism and Targeting of Chronic Pain in Sickle Cell Disease$1,103,783
R35 · FY2025 · HL · contact PI
α9α10 Nicotinic Acetylcholine Receptors in neuropathic pain$624,360
R01 · FY2025 · NS
Exploring the Mediterranean Diet as A Promising Approach for Alleviating Chronic Pain in Sickle Cell Disease$437,458
R21 · FY2025 · AT
Molecular mechanism and targeting of chronic pain in sickle cell disease$648,171
R35 · FY2024 · HL · contact PI
α9α10 Nicotinic Acetylcholine Receptors in neuropathic pain$624,360
R01 · FY2024 · NS
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2023 · HL · contact PI
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2022 · HL · contact PI
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2021 · HL · contact PI
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2020 · HL · contact PI
Cortical opioid dysfunction in chronic pain$531,442
R01 · FY2020 · DA
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2019 · HL · contact PI
Cortical opioid dysfunction in chronic pain$533,969
R01 · FY2019 · DA
Molecular mechanism and targeting of chronic pain in sickle cell disease$661,398
R35 · FY2018 · HL · contact PI
Cortical opioid dysfunction in chronic pain$541,897
R01 · FY2018 · DA
HL-Phenotypic Characterization of Chronic Pain in Adults with Sickle Cell Disease$823,373
R01 · FY2017 · HL
Cortical opioid dysfunction in chronic pain$550,005
R01 · FY2017 · DA
Protein kinase mechanisms for chronic pain in sickle cell disease$398,136
R01 · FY2017 · HL · contact PI
Cortical opioid dysfunction in chronic pain$8,375
R01 · FY2017 · DA
HL-Phenotypic Characterization of Chronic Pain in Adults with Sickle Cell Disease$827,237
R01 · FY2016 · HL
Cortical opioid dysfunction in chronic pain$567,508
R01 · FY2016 · DA
Protein kinase mechanisms for chronic pain in sickle cell disease$404,011
R01 · FY2016 · HL · contact PI
HL-Phenotypic Characterization of Chronic Pain in Adults with Sickle Cell Disease$779,804
R01 · FY2015 · HL
HL-Phenotypic Characterization of Chronic Pain in Adults with Sickle Cell Disease$30,780
R01 · FY2015 · HL
HL-Phenotypic Characterization of Chronic Pain in Adults with Sickle Cell Disease$778,692
R01 · FY2014 · HL
CaMKII as a Mechanism & Intervention Target for Sickle Cell Pain$422,628
R01 · FY2013 · HL · contact PI
Academic Career Development in Botanical Dietary Supplements$135,192
K07 · FY2012 · AT · contact PI
CaMKII as a Mechanism & Intervention Target for Sickle Cell Pain$447,922
R01 · FY2011 · HL · contact PI
Pain in Sickle Cell Disease: Basic & Clinical Science Advances and Future Directi$7,500
R13 · FY2011 · HL · contact PI
CaMKII as a Mechanism & Intervention Target for Sickle Cell Pain$445,484
R01 · FY2010 · HL · contact PI
Molecular mechanisms of Angelica sinensis (Oliv.) Diels in women's health$233,145
R21 · FY2010 · AT · contact PI
Academic Career Development in Botanical Dietary Supplements$135,192
K07 · FY2010 · AT · contact PI
CaMKII as a Mechanism & Intervention Target for Sickle Cell Pain$448,200
R01 · FY2009 · HL · contact PI
Molecular mechanisms of Angelica sinensis (Oliv.) Diels in women?s health$190,550
R21 · FY2009 · AT · contact PI
Molecular mechanisms of Angelica sinensis (Oliv.) Diels in women's health$145,600
R21 · FY2009 · AT · contact PI
Academic Career Development in Botanical Dietary Supplements$135,192
K07 · FY2009 · AT · contact PI
Academic Career Development in Botanical Dietary Supplements$135,192
K07 · FY2008 · AT · contact PI
CNS mechanisms of black cohosh in menopause$188,131
R21 · FY2007 · AT · contact PI
Academic Career Development in Botanical Dietary Supplements$135,192
K07 · FY2007 · AT · contact PI
CNS mechanisms of black cohosh in menopause$188,250
R21 · FY2006 · AT · contact PI
Molecular mechanisms of Vitex agnus-castus L. in PMS$186,136
R21 · FY2005 · AT
Molecular mechanisms of Vitex agnus-castus L. in PMS$185,019
R21 · FY2004 · AT
DYNORPHIN MODULATES CGRP RELEASE VIA PKC$120,340
K01 · FY2003 · DA
DYNORPHIN MODULATES CGRP RELEASE VIA PKC$118,122
K01 · FY2002 · DA
DYNORPHIN MODULATES CGRP RELEASE VIA PKC$69,702
K01 · FY2001 · DA
DYNORPHIN MODULATES CGRP RELEASE VIA PKC$35,914
K01 · FY2001 · DA